~~<i id='A3A1584957'><strike id='A3A1584957'><tt id='A3A1584957'><pre id='A3A1584957'></pre></tt></strike></i>~~

Home» focus» focus

focus

author：leisure time 2025-09-27 13:14:34 Page View：75

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Blood tests recalled over risk of missed heart attack diagnosis
Next article： How one medical school became remarkably diverse

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Gilead might be held responsible for not developing a drug

JustinSullivan/GettyImagesTheassaultonthedevelopmentofnewlifesavingtherapiescontinuesapace.Recently,

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Biogen Alzheimer’s drug launch off to slow start

Illustration:AlexHogan/STAT;Photo:EisaiviaAPSevenmonthsafterUSdrugregulatorsfullyapprovedBiogen’stre

WSS

focus

focus

knowledge

leisure time

Biogen Alzheimer’s drug launch off to slow start